Inmed Pharmaceuticals INC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
NASDAQ
InMed Pharmaceuticals Inc. filed an S-1/A registration statement for the resale of common shares by a selling shareholder, while detailing its drug development pipeline, financial results, and ongoing capital needs.
NASDAQ
InMed Pharmaceuticals Inc. has filed an S-1 registration statement to allow a selling shareholder to resell up to 3,904,726 common shares, stemming from a recent private placement that provided the company with potential proceeds of approximately $4.76 million from warrant and option exercises, while the company continues to face significant operating losses and a substantial accumulated deficit.
NASDAQ
S-1/A: InMed Pharmaceuticals Files Amendment to S-1 Registration Statement for Common Share Offering
InMed Pharmaceuticals has filed a pre-effective amendment to its S-1 registration statement, primarily to include updated legal opinions and consents related to a potential offering of common shares.
NASDAQ
S-1: InMed Pharmaceuticals Files for Resale of 3 Million Common Shares Under Standby Equity Agreement
InMed Pharmaceuticals has filed a registration statement for the potential resale of up to 3 million common shares by a selling shareholder, following a Standby Equity Purchase Agreement.